復銳醫療科技(01696.HK):RT002相關藥品註冊申請獲受理
復銳醫療科技(01696.HK)公布,由復星產業再授權產品RT002(DaxibotulinumtoxinA型肉毒桿菌毒素)用於暫時性改善成人因皺眉肌或降眉間肌活動引起的中度至重度皺眉紋的藥品註冊申請於近日獲國家藥品監督管理局審評受理。目前於中國境內尚無DaxibotulinumtoxinA型肉毒桿菌毒素的產品上市銷售。
公司於去年12月獲復星產業再授權關於RT002在區域內,即中國內地、香港及澳門特別行政區使用、進口、銷售及其他商業化的權利許可,原授權方美國Revance Therapeutics, Inc.仍為該新藥在區域內的權利人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.